Company Performance - 4D Molecular Therapeutics reported a quarterly loss of $0.98 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.88, and compared to a loss of $0.63 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $0.02 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 98.58%, while revenues were zero a year ago [2] - The stock has added about 1.1% since the beginning of the year, underperforming the S&P 500's gain of 8.6% [3] Earnings Outlook - The current consensus EPS estimate for the coming quarter is -$0.93 on revenues of $1.06 million, and for the current fiscal year, it is -$3.45 on revenues of $4.17 million [7] - The estimate revisions trend for 4D Molecular Therapeutics was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting expected outperformance in the near future [6] Industry Context - The Medical - Drugs industry, to which 4D Molecular Therapeutics belongs, is currently in the top 35% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Inotiv, Inc. (NOTV) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.2 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +20.00%. A quarter ago, it was expected that this company would post a loss of $0.24 per share when it actually produced a loss of $0.18, delivering a surprise of +25%.Over the last four quarters, the company has surpassed c ...

Company Performance - Indivior PLC reported quarterly earnings of $0.51 per share, exceeding the Zacks Consensus Estimate of $0.26 per share, and up from $0.44 per share a year ago, representing an earnings surprise of +96.15% [1] - The company posted revenues of $302 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 22.05%, compared to revenues of $299 million in the same quarter last year [2] - Over the last four quarters, Indivior has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - Indivior shares have increased approximately 40% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.2% [3] - The current consensus EPS estimate for the upcoming quarter is $0.26 on revenues of $253.66 million, and for the current fiscal year, it is $1.21 on revenues of $1.02 billion [7] Industry Outlook - The Medical - Drugs industry, to which Indivior belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Core Insights - Zoetis is positioned to continue its earnings-beat streak, particularly in the upcoming earnings report, with a history of positive surprises in recent quarters [1][5] - The company reported earnings of $1.48 per share for the last quarter, exceeding the Zacks Consensus Estimate of $1.4 per share by 5.71% [2] - The previous quarter also saw a positive surprise, with actual earnings of $1.4 per share against an expected $1.37 per share, resulting in a 2.19% surprise [2] Earnings Estimates and Predictions - Estimates for Zoetis have been trending higher, supported by its history of earnings surprises [5] - The stock has a positive Zacks Earnings ESP of +1.10%, indicating bullish sentiment among analysts regarding the company's earnings prospects [8] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a strong likelihood of another earnings beat in the upcoming report [8] Earnings ESP and Market Behavior - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 or better have a nearly 70% chance of producing a positive surprise [6] - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions [7] - A negative Earnings ESP can reduce predictive power but does not necessarily indicate an earnings miss [9]

Core Viewpoint - Ionis Pharmaceuticals (IONS) experienced a significant stock price increase of 9.1% to $43.59, driven by investor optimism regarding its drug portfolio and pipeline expansion [1][2]. Company Performance - The company is expected to report quarterly earnings of $0.19 per share, reflecting a year-over-year increase of 142.2%. Revenue is anticipated to be $246.31 million, up 9.5% from the same quarter last year [3]. - However, the consensus EPS estimate has been revised 5.5% lower over the past 30 days, indicating a negative trend in earnings estimate revisions, which typically does not lead to price appreciation [4]. Industry Context - Ionis Pharmaceuticals is part of the Zacks Medical - Drugs industry, where another company, Crinetics Pharmaceuticals, Inc. (CRNX), saw a 3.6% increase in its stock price but has returned -11.4% over the past month [5]. - Crinetics Pharmaceuticals has an unchanged consensus EPS estimate of -$1.13, representing a year-over-year change of -20.2% [6].

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Catalyst Pharmaceutical (CPRX) - Catalyst Pharmaceutical currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 2 (Buy), suggesting it is positioned for potential outperformance in the market [3] Price Performance - CPRX shares have increased by 1.92% over the past week, while the Zacks Medical - Drugs industry remained flat [5] - Over the past month, CPRX's price change is 8.02%, outperforming the industry's 3.76% [5] - In the last quarter, shares of CPRX have risen by 18.84%, and over the past year, they have gained 55.3%, compared to the S&P 500's increases of 2.37% and 14.4%, respectively [6] Trading Volume - The average 20-day trading volume for CPRX is 1,094,588 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the past two months, four earnings estimates for CPRX have been revised upwards, while none have been revised downwards, leading to an increase in the consensus estimate from $2.15 to $2.25 [9] - For the next fiscal year, three estimates have moved up, while one has been revised down [9] Conclusion - Considering the strong momentum indicators and positive earnings outlook, CPRX is identified as a 2 (Buy) stock with a Momentum Score of A, making it a potential candidate for near-term investment [11]